Genix Pharmaceuticals (GENX) Stock Statistics & Valuation Metrics

Genix Pharmaceuticals has a market cap or net worth of C$918.36K. The enterprise value is C$2.80M.

Genix Pharmaceuticals has 61,224,133 shares outstanding. The number of shares has decreased by -2.65% in one year.

Genix Pharmaceuticals’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Genix Pharmaceuticals is ―. Genix Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Genix Pharmaceuticals had revenue of ― and earned -4.40M in profits. Earnings per share was ―.

In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.

Genix Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Genix Pharmaceuticals upcoming earnings date is Sep 17, 2026, TBA (Confirmed).

Genix Pharmaceuticals as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, Genix Pharmaceuticals has paid ― in taxes.

Genix Pharmaceuticals EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Genix Pharmaceuticals has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for Genix Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―